RT Journal Article
T1 Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy
A1 Sánchez Barroso, Lara
A1 Apellaniz Ruiz, Maria
A1 Gutiérrez Gutiérrez, Gerardo
A1 Santos, María
A1 Roldán Romero, Juan M.
A1 Curras, Maria
A1 Remacha, Laura
A1 Calsina, Bruna
A1 Calvo, Isabel
A1 Sereno, María
A1 Merino, María
A1 García Donas, Jesús
A1 Castelo, Beatriz
A1 Guerra, Eva
A1 Letón, Rocio
A1 Montero Conde, Cristina
A1 Cascón, Alberto
A1 Inglada Pérez, Lucía Silvia
A1 Robledo, Mercedes
A1 Rodríguez Antona, Cristina
AB Background. Peripheral neuropathy is the dose-limiting toxicity of many oncology drugs, including paclitaxel. There is large interindividual variability in the neuropathy, and several risk factors have been proposed; however, many have not been replicated. Here we present a comprehensive study aimed at identifying treatment and physiopathology-related paclitaxel-induced neuropathy risk factors in a large cohort of well-characterized patients.Patients and Methods. Analyses included 503 patients with breast or ovarian cancer who received paclitaxel treatment. Paclitaxel dose modifications caused by the neuropathy were extracted from medical records and patients self-reported neuropathy symptoms were collected. Multivariate logistic regression analyses were performed to identify concomitant medications and comorbidities associated with paclitaxel-induced neuropathy.Results. Older patients had higher neuropathy: for each increase of 1 year of age, the risk of dose modifications and grade 3 neuropathy increased 4% and 5%, respectively.Cardiovascular drugs increased the risk of paclitaxel dose reductions (odds ratio [OR], 2.51; p = .006), with a stronger association for beta-adrenergic antagonists. The total number of concomitant medications also showed an association with dose modifications (OR, 1.25; p = .012 for each concomitant drug increase). A dose modification predictivemodel that included the new identified factors gave an area under the curve of 0.74 (p = 1.07 × 10−10). Preexisting nerve compression syndromes seemed to increase neuropathy risk.Conclusion. Baseline characteristics of the patients, including age and concomitant medications, could be used to identify individuals at high risk of neuropathy, personalizingchemotherapy treatment and reducing the risk of severe neuropathy.
PB Oxford Academic
SN 1083-7159
SN 1549-490X
YR 2018
FD 2018-11-23
LK https://hdl.handle.net/20.500.14352/94378
UL https://hdl.handle.net/20.500.14352/94378
LA eng
NO Lara Sánchez‐Barroso, Maria Apellaniz‐Ruiz, Gerardo Gutiérrez‐Gutiérrez, María Santos, Juan M. Roldán‐Romero, Maria Curras, Laura Remacha, Bruna Calsina, Isabel Calvo, María Sereno, María Merino, Jesús García‐Donas, Beatriz Castelo, Eva Guerra, Rocio Letón, Cristina Montero‐Conde, Alberto Cascón, Lucía Inglada‐Pérez, Mercedes Robledo, Cristina Rodríguez‐Antona, Concomitant Medications and Risk of Chemotherapy‐Induced Peripheral Neuropathy, The Oncologist, Volume 24, Issue 8, August 2019, Pages e784–e792, https://doi.org/10.1634/theoncologist.2018-0418
DS Docta Complutense
RD 8 abr 2025